Editorial review · United States
Teduglutide
Source review:
Approval and product status
Teduglutide is a 33-amino-acid GLP-2 analog. In the United States, Gattex (teduglutide) is FDA-approved for people age 1 and older who have short bowel syndrome and depend on fluids or nutrition given through a vein.
Gattex evidence applies to a specific monitored prescription product. Gattex is a labeled prescription product used with structured monitoring. Its evidence does not establish general gut healing or equivalence for compounded GLP-2 analogues.
This is the status described in the dated review. It is not a live FDA database check.
What was measured in people?
- Health outcomes · Strong
- Randomized trials support reduction in parenteral-support requirements for short bowel syndrome.
- Body effects · Strong
- Intestinal absorption, exposure, and product effects are characterized in the label and trials.
A change in a hormone or body signal does not by itself prove a health benefit.
Limits that matter
Not independently medically reviewed. This tool does not recommend treatment.
This monitored prescription therapy has serious risks, including possible acceleration of neoplastic growth. No dosing, reconstitution, or self-treatment guidance is provided.
Still unknown: The evidence does not establish broad treatment of leaky gut, inflammatory symptoms, wellness, or mucosal repair in people without the labeled syndrome.
This record cannot check a package, seller, batch, or personal treatment. It does not provide sport clearance.
Exact product records in this review
These are selected records, not every product or form. A route means how a product enters the body.
Gattex
- Form
- Powder and diluent for injection
- Route
- Subcutaneous
- Use and limits
- Short bowel syndrome with parenteral-support dependence in the adult and pediatric populations defined in the label.
Published label: 2025 label
Read the published Gattex FDA label (PDF)What the research shows
Randomized trials found that some participants needed less fluid or nutrition through a vein. The product label defines required screening and ongoing monitoring.
Read all Teduglutide claims and their limitsSources used in the full review
A source is not support for every claim. Use the claim links above or the full review to check what each source supports.
- GATTEX (teduglutide) prescribing information
U.S. Food and Drug Administration · Drug label · 2025
Source accessed
- Teduglutide reduces parenteral support in short bowel syndrome
PubMed · Gastroenterology · Randomized trial · 2012
Source accessed
- Teduglutide orphan drug designation and approval
U.S. Food and Drug Administration · Regulatory · 2019
Source accessed